Dialysis heavyweights punch well in second quarter
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences says net sales increased by 4%, excluding the effect of foreign exchange and divested businesses. In the company's cardiac surgery division, sales were $85 million, up 10%. Growth continues to be led by robust sales of its pericardial tissue valve products. Critical care sales rose 7% to $54 million. Edwards says it is benefiting from the continued trend of customers to more advanced technology catheter products. Vascular sales fell 3% to $13 million. The company says it is on track to re-enter the European market with its Lifepath AAA Endovascular graft system, as well as resuming US clinical trials of the product, by the end of the year. Edwards voluntarily halted European sales and US clinical trials of the device after it found a fracture in the product's wireform in April 2000 (see Clinica No 906, p 1). Edwards expects a 20% increase in net income for the full year.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.